share_log

Transcode Therapeutics | 424B5: Prospectus

Transcode Therapeutics | 424B5: Prospectus

Transcode Therapeutics | 424B5:募資說明書
美股SEC公告 ·  2024/07/22 16:13

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc. has announced the offering of common stock, pre-funded warrants to purchase common stock, and shares of common stock issuable upon the exercise of pre-funded warrants. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. The prospectus supplement, dated July 22, 2024, outlines the terms of the offering, including the purchase price of shares and pre-funded warrants, the immediate exercisability of the pre-funded warrants, and the lack of an established trading market for the pre-funded warrants. TransCode has engaged ThinkEquity LLC as the exclusive placement agent for the offering, which is on a best-efforts basis with no minimum offering requirement. The proceeds are intended for product development activities, clinical trials, working capital, and other general corporate purposes. The offering is expected to close on or about July, 2024, subject to customary closing conditions.
TransCode Therapeutics, Inc. has announced the offering of common stock, pre-funded warrants to purchase common stock, and shares of common stock issuable upon the exercise of pre-funded warrants. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. The prospectus supplement, dated July 22, 2024, outlines the terms of the offering, including the purchase price of shares and pre-funded warrants, the immediate exercisability of the pre-funded warrants, and the lack of an established trading market for the pre-funded warrants. TransCode has engaged ThinkEquity LLC as the exclusive placement agent for the offering, which is on a best-efforts basis with no minimum offering requirement. The proceeds are intended for product development activities, clinical trials, working capital, and other general corporate purposes. The offering is expected to close on or about July, 2024, subject to customary closing conditions.
TransCode Therapeutics, Inc.宣佈發行普通股、預先融資認股權和行使預先融資認股權而發行的普通股。該發行在《證券法》第424(b)(5)條下備案的招股說明書補充中有詳細說明。招股說明書補充,於2024年7月22日發佈,概述了發行股票和預先融資認股權的購買價格、預先融資認股權的立即行使性以及預先融資認股權的交易市場的缺失情況等發行條款。TransCode已委託ThinkEquity LLC作爲發行的獨家配售代理,發行是盡力而爲的,沒有最低認購需求。所得款項將用於產品開發活動、臨床試驗、營運資金和其他一般企業用途。該發行預計於2024年7月左右結束,但須符合慣常的證券交易結束條件。
TransCode Therapeutics, Inc.宣佈發行普通股、預先融資認股權和行使預先融資認股權而發行的普通股。該發行在《證券法》第424(b)(5)條下備案的招股說明書補充中有詳細說明。招股說明書補充,於2024年7月22日發佈,概述了發行股票和預先融資認股權的購買價格、預先融資認股權的立即行使性以及預先融資認股權的交易市場的缺失情況等發行條款。TransCode已委託ThinkEquity LLC作爲發行的獨家配售代理,發行是盡力而爲的,沒有最低認購需求。所得款項將用於產品開發活動、臨床試驗、營運資金和其他一般企業用途。該發行預計於2024年7月左右結束,但須符合慣常的證券交易結束條件。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息